SAN DIEGO—John Nuss, the Chief Scientific Officer of Ventyx Biosciences, Inc. (NASDAQ:VTYX), recently sold a portion of his holdings in the company. According to a recent SEC filing, Nuss sold 21,119 shares of Ventyx Biosciences stock on December 27, 2024. The shares were sold at a weighted average price of approximately $2.36, amounting to a total transaction value of $49,840. The transaction comes as the stock trades near its 52-week low of $1.67, with the company’s market capitalization currently standing at $168 million. InvestingPro analysis indicates the stock is currently undervalued based on its Fair Value assessment.
Following this sale, Nuss retains ownership of 464,582 shares in the company. The sales were conducted as part of regular portfolio management and do not necessarily indicate any changes in the executive’s confidence in the company. While InvestingPro data shows the company maintains strong liquidity with a current ratio of 23.52 and holds more cash than debt, it’s worth noting that four analysts have recently revised their earnings expectations downward. Subscribers to InvestingPro can access detailed insider trading patterns and eight additional key insights about VTYX’s financial health.
In other recent news, Ventyx Biosciences has reported encouraging results from its Phase 2 study of tamuzimod for ulcerative colitis, with significant remission rates observed. The company also announced a $27 million investment from pharmaceutical giant Sanofi (NASDAQ:), tied to Ventyx’s drug candidate for Parkinson’s disease and obesity, VTX3232. A leadership transition has also taken place, with CFO Martin Auster stepping down and Roy Gonzales stepping up as interim Principal Financial (NASDAQ:) Officer and Principal Accounting Officer.
Analyst notes indicate that H.C. Wainwright has maintained its Neutral rating for Ventyx Biosciences, while Piper Sandler has kept its Overweight rating. Oppenheimer, on the other hand, has reduced its price target but retained an Outperform rating. The company reported a net quarterly loss of $38.6 million, with cash, cash equivalents, and marketable securities totaling $279.7 million.
Additionally, Ventyx’s drug, VTX958, showed a positive impact on a key secondary endpoint in its Phase 2 trial for Crohn’s disease, despite not meeting its primary goal. However, Ventyx has stated it will not conduct further trials of VTX958 with its internal resources. These are among the recent developments in the company’s operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
